Innovation Fund assesses Kenyan market for new FDA-approved LNG-IUS
13th March 2015
An Innovation Fund grant has helped launch a partnership designed to broaden options for long-acting reversible contraception in the Kenyan market. With the grant’s support, three Coalition members -- FHI360, Medicines360, and Marie Stopes International -- are developing a national introduction strategy in Kenya for Medicine360’s newly FDA-approved levonorgestrel-releasing intrauterine system (LNG-IUS). A market assessment found that clients in the private sector are paying between US$56 and US$194 for the LNG-IUS product currently marketed in Kenya, making it prohibitively expensive for most women.
Medicines360 and Actavis recently announced the approval of their product (which will be marketed as LILETTA™ the US) by the U.S. Food and Drug Administration (FDA) for use by women to prevent pregnancy for up to three years. The product will be affordably priced in both the developed and the developing world to increase equitable access and choice for women globally. For more information about the FDA approval of LILETTA, please contact email@example.com. For more information about the Innovation Fund project, please contact firstname.lastname@example.org.
Categories: Shaping Markets